- Science 37 and Catalent announced a partnership to deliver investigational medicinal products (IMPs) directly to patients’ homes for clinical trials.
- The collaboration has supported 17 studies, enrolling nearly 1,700 patients and completing more than 6,400 shipments.
Science 37 and Catalent have announced a strategic partnership to expand access to clinical trials by delivering investigational medicinal products (IMPs) directly to patients’ homes. The collaboration supports Science 37’s Direct-to-Patient Clinical Trial Site model with Catalent providing logistics and shipping services.
The partnership has been applied across 17 studies, enrolling nearly 1,700 patients through at-home trial participation. On average, a single Direct-to-Patient Site enrolled 26% of total study participants, equivalent to more than 15 traditional brick-and-mortar sites, with nine patients recruited per month. To date, the collaboration has delivered over 6,400 shipments to participants.
The integrated model offers trial sponsors a single contract and budget covering site operations, supply chain and visit execution. According to the companies, this structure streamlines clinical research, improves patient retention and broadens participation to underserved and geographically dispersed populations.
“Catalent’s expertise in direct-to-patient logistics is a key enabler of our mission to expand access to clinical trials,” said Tyler Van Horn, CEO at Science 37. “By removing geographic barriers, we’re not only reaching more diverse patient populations, we’re also driving faster enrollment and generating high-quality data that helps bring treatments to market sooner.”
The companies stated that the partnership is designed to make clinical research more patient-centred while maintaining the precision and operational standards expected by trial sponsors.
